| Literature DB >> 26560494 |
Ravi A Madan1, James L Gulley1.
Abstract
Cancer therapy is undergoing a revolution fueled by clinical data demonstrating that the immune system has significant anti-tumor capability. Although the main focus of this revolution currently rests upon immune checkpoint inhibitors in diseases such as melanoma, lung and bladder cancer, it was actually a therapeutic cancer vaccine in prostate cancer that provided the first data demonstrating that a modern immunotherapy, beyond cytokines, could enhance clinical outcomes. As immunotherapy is poised to take center stage among cancer therapies, the role of cancer vaccines remains somewhat undefined in prostate cancer, though emerging data suggest that vaccines could play a crucial therapeutic role.Entities:
Keywords: Vaccines; combination therapy; immune combinations; prostate cancer; therapeutic cancer vaccines
Mesh:
Substances:
Year: 2015 PMID: 26560494 PMCID: PMC6641856 DOI: 10.1586/14760584.2015.1118348
Source DB: PubMed Journal: Expert Rev Vaccines ISSN: 1476-0584 Impact factor: 5.217